CL2011002524A1 - Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c. - Google Patents

Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c.

Info

Publication number: CL2011002524A1
Authority: CL; Chile
Prior art keywords: phenyl; substituted; diazol; diazole; ethenyl
Prior art date: 2009-04-09

Application number

CL2011002524A

Other languages

English (en)

Inventor

Makonen Kadow John F Belema

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-09

Filing date

2011-10-07

Publication date

2012-03-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42244128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002524(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-07 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2012-03-23 Publication of CL2011002524A1 publication Critical patent/CL2011002524A1/es

Links

101710188663 Non-structural protein 5a Proteins 0.000 title 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 title 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
208000006454 hepatitis Diseases 0.000 title 1
231100000283 hepatitis Toxicity 0.000 title 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

CL2011002524A 2009-04-09 2011-10-07 Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c. CL2011002524A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16798909P	2009-04-09	2009-04-09

Publications (1)

Publication Number	Publication Date
CL2011002524A1 true CL2011002524A1 (es)	2012-03-23

Family

ID=42244128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2011002524A CL2011002524A1 (es)	2009-04-09	2011-10-07	Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c.

Country Status (22)

Country	Link
US (1)	US8143301B2 (es)
EP (1)	EP2417126B1 (es)
JP (1)	JP5558556B2 (es)
KR (1)	KR20120133366A (es)
CN (1)	CN102803249B (es)
AR (1)	AR076274A1 (es)
AU (1)	AU2010234608B2 (es)
BR (1)	BRPI1010506A2 (es)
CA (1)	CA2757963A1 (es)
CL (1)	CL2011002524A1 (es)
CO (1)	CO6440581A2 (es)
EA (1)	EA018793B1 (es)
ES (1)	ES2502667T3 (es)
IL (1)	IL215095A0 (es)
MX (1)	MX2011010478A (es)
MY (1)	MY152971A (es)
NZ (1)	NZ595186A (es)
PE (1)	PE20120533A1 (es)
SG (1)	SG174582A1 (es)
TW (1)	TW201038559A (es)
WO (1)	WO2010117977A1 (es)
ZA (1)	ZA201107095B (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG172352A1 (en)	2008-12-23	2011-07-28	Abbott Lab	Anti-viral compounds
US8546405B2 (en)	2008-12-23	2013-10-01	Abbott Laboratories	Anti-viral compounds
US8314135B2 (en) *	2009-02-09	2012-11-20	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole antivirals
TWI438200B (zh) *	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8188132B2 (en)	2009-02-17	2012-05-29	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8394968B2 (en)	2009-02-17	2013-03-12	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8242156B2 (en)	2009-02-17	2012-08-14	Enanta Pharmaceuticals, Inc.	Linked dibenzimidazole derivatives
US8673954B2 (en)	2009-02-27	2014-03-18	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8101643B2 (en) *	2009-02-27	2012-01-24	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US9765087B2 (en)	2009-02-27	2017-09-19	Enanta Pharmaceuticals, Inc.	Benzimidazole derivatives
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9278922B2 (en) *	2009-04-15	2016-03-08	Abbvie Inc.	Anti-viral compounds
HUE030465T2 (hu)	2009-05-13	2017-05-29		Antivirális vegyületek
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8937150B2 (en)	2009-06-11	2015-01-20	Abbvie Inc.	Anti-viral compounds
US8716454B2 (en)	2009-06-11	2014-05-06	Abbvie Inc.	Solid compositions
EA020031B1 (ru)	2009-06-11	2014-08-29	Эббви Бахамаз Лтд.	Противовирусные соединения
US9394279B2 (en)	2009-06-11	2016-07-19	Abbvie Inc.	Anti-viral compounds
US8221737B2 (en) *	2009-06-16	2012-07-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8609648B2 (en)	2009-07-02	2013-12-17	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
AU2010274001A1 (en)	2009-07-16	2012-02-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of Flavivirus infections
CN102480971B (zh)	2009-09-04	2014-11-26	杨森制药公司	化合物
US8822700B2 (en) *	2009-09-11	2014-09-02	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8703938B2 (en) *	2009-09-11	2014-04-22	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8815928B2 (en)	2009-09-11	2014-08-26	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8759332B2 (en) *	2009-09-11	2014-06-24	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8927709B2 (en) *	2009-09-11	2015-01-06	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US9156818B2 (en) *	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110137633A1 (en) *	2009-12-03	2011-06-09	Abbott Laboratories	Anti-viral compounds and methods of identifying the same
US8653070B2 (en) *	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20110152246A1 (en) *	2009-12-18	2011-06-23	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
US8362020B2 (en)	2009-12-30	2013-01-29	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8933110B2 (en)	2010-01-25	2015-01-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
PE20130244A1 (es)	2010-01-25	2013-03-10	Enanta Pharm Inc	Inhibidores del virus de la hepatitis c
US8178531B2 (en) *	2010-02-23	2012-05-15	Enanta Pharmaceuticals, Inc.	Antiviral agents
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
CN102858157A (zh) *	2010-03-04	2013-01-02	埃南塔制药公司	作为hcv复制的抑制剂的组合药物活性剂
CN102869657A (zh)	2010-03-24	2013-01-09	沃泰克斯药物股份有限公司	用于治疗或预防黄病毒感染的类似物
EP2555622A4 (en)	2010-04-09	2013-09-18	Enanta Pharm Inc	HEPATITIS C-VIRUS HEMMER
US8778938B2 (en)	2010-06-04	2014-07-15	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
NZ605440A (en)	2010-06-10	2014-05-30	Abbvie Bahamas Ltd	Solid compositions comprising an hcv inhibitor
WO2012006060A1 (en)	2010-06-28	2012-01-12	Vertex Pharmaceuticals Incorporated	Compounds and methods for the treatment or prevention of flavivirus infections
EP2585447A2 (en)	2010-06-28	2013-05-01	Vertex Pharmaceuticals Incorporated	Compounds and methods for the treatment or prevention of flavivirus infections
WO2012021704A1 (en)	2010-08-12	2012-02-16	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
EP2606041A2 (en)	2010-08-17	2013-06-26	Vertex Pharmaceuticals Incorporated	Compounds and methods for the treatment or prevention of flaviviridae viral infections
RU2452735C1 (ru)	2010-11-30	2012-06-10	Александр Васильевич Иващенко	Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
JP5906253B2 (ja) *	2010-12-16	2016-04-20	アッヴィ・インコーポレイテッド	抗ウイルス性化合物
CA2822357A1 (en)	2010-12-22	2012-06-28	Abbvie Inc.	Hepatitis c inhibitors and uses thereof
US8552047B2 (en)	2011-02-07	2013-10-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9546160B2 (en)	2011-05-12	2017-01-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
WO2012158861A2 (en)	2011-05-18	2012-11-22	Enanta Pharmaceuticals, Inc.	Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
AU2012286853A1 (en)	2011-07-26	2013-05-02	Vertex Pharmaceuticals Incorporated	Thiophene compounds
WO2013016499A1 (en)	2011-07-26	2013-01-31	Vertex Pharmaceuticals Incorporated	Methods for preparation of thiophene compounds
WO2013030750A1 (en)	2011-09-01	2013-03-07	Lupin Limited	Antiviral compounds
EP2709613B2 (en)	2011-09-16	2020-08-12	Gilead Pharmasset LLC	Methods for treating hcv
US9034832B2 (en)	2011-12-29	2015-05-19	Abbvie Inc.	Solid compositions
US9326973B2 (en)	2012-01-13	2016-05-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
AU2013217224B2 (en)	2012-02-10	2017-04-06	Lupin Limited	Antiviral compounds with a dibenzooxaheterocycle moiety
WO2013142157A1 (en)	2012-03-22	2013-09-26	Alios Biopharma, Inc.	Pharmaceutical combinations comprising a thionucleotide analog
EP2950786B1 (en)	2013-01-31	2019-11-27	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
RU2507201C1 (ru)	2013-02-07	2014-02-20	Александр Васильевич Иващенко	Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
WO2014134251A1 (en)	2013-02-28	2014-09-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions
US11484534B2 (en)	2013-03-14	2022-11-01	Abbvie Inc.	Methods for treating HCV
US20150023913A1 (en)	2013-07-02	2015-01-22	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US9717712B2 (en)	2013-07-02	2017-08-01	Bristol-Myers Squibb Company	Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US9775831B2 (en)	2013-07-17	2017-10-03	Bristol-Myers Squibb Company	Combinations comprising biphenyl derivatives for use in the treatment of HCV
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais
WO2015103490A1 (en)	2014-01-03	2015-07-09	Abbvie, Inc.	Solid antiviral dosage forms
WO2017023631A1 (en)	2015-08-06	2017-02-09	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
KR102497854B1 (ko)	2017-11-12	2023-02-07	대우조선해양 주식회사	함 내 연료전지 운용 시스템 및 운용 방법
US12037340B2 (en)	2021-05-21	2024-07-16	Gilead Sciences, Inc.	Pentacyclic derivatives as Zika virus inhibitors
US12497408B2 (en)	2021-05-21	2025-12-16	Gilead Sciences, Inc.	Tetracyclic compounds and methods for the treatment of Zika virus infection

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH08505854A (ja)	1993-01-14	1996-06-25	マガイニンファーマシューティカルズ，インク．	修飾された末端を有するアミノ酸及びペプチド
US5654451B1 (en) *	1993-01-14	2000-02-22	Magainin Pharma	Amino acids and peptides having modified c-terminals and modified n-terminals
AU2003249977A1 (en)	2002-07-05	2004-01-23	Axxima Pharmaceuticals Ag	Imidazole compounds for the treatment of hepatitis c virus infections
PE20060426A1 (es) *	2004-06-02	2006-06-28	Schering Corp	DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
WO2006022442A1 (ja)	2004-08-24	2006-03-02	Santen Pharmaceutical Co., Ltd.	ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006093867A1 (en)	2005-02-28	2006-09-08	The Rockefeller University	Structure of the hepatitits c virus ns5a protein
US8143288B2 (en)	2005-06-06	2012-03-27	Bristol-Myers Squibb Company	Inhibitors of HCV replication
EP1940786B1 (en)	2005-09-16	2010-08-18	Arrow Therapeutics Limited	Biphenyl derivatives and their use in treating hepatitis c
WO2007058384A1 (en)	2005-11-17	2007-05-24	Osaka University	Method of suppressing replication of hepatitis c virus, inhibitor of replication of the virus and method of screening for the same
WO2007081517A2 (en)	2005-12-21	2007-07-19	Abbott Laboratories	Anti-viral compounds
US7910595B2 (en)	2005-12-21	2011-03-22	Abbott Laboratories	Anti-viral compounds
SG133452A1 (en)	2005-12-30	2007-07-30	Novartis Ag	Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
KR20090012345A (ko)	2006-05-30	2009-02-03	애로우 쎄라퓨틱스 리미티드	바이페닐 유도체, 및 ｃ형 간염 치료에 있어서의 이들의 용도
ES2745411T3 (es)	2006-07-27	2020-03-02	Wang Nai Fang	Compuestos y composiciones de arilsulfanilo para administración de agentes activos
US8329159B2 (en)	2006-08-11	2012-12-11	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7759495B2 (en)	2006-08-11	2010-07-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US7659270B2 (en)	2006-08-11	2010-02-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US20100158862A1 (en) *	2006-08-11	2010-06-24	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US8303944B2 (en) *	2006-08-11	2012-11-06	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP2010510245A (ja)	2006-11-21	2010-04-02	スミスクラインビーチャムコーポレーション	抗ウイルス化合物
US8236950B2 (en)	2006-12-20	2012-08-07	Abbott Laboratories	Anti-viral compounds
US8629171B2 (en)	2007-08-08	2014-01-14	Bristol-Myers Squibb Company	Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US7728027B2 (en)	2007-08-08	2010-06-01	Bristol-Myers Squibb Company	Process for synthesizing compounds useful for treating hepatitis C
DK2250163T3 (da)	2008-02-12	2012-07-16	Bristol Myers Squibb Co	Hepatitis C-virusinhibitorer
KR20100123717A (ko)	2008-02-12	2010-11-24	브리스톨-마이어스 스큅 컴퍼니	Ｃ형 간염 바이러스 억제제로서의 헤테로시클릭 유도체
US7704992B2 (en)	2008-02-13	2010-04-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8147818B2 (en)	2008-02-13	2012-04-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2009102325A1 (en)	2008-02-13	2009-08-20	Bristol-Myers Squibb Company	Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US7906655B2 (en)	2008-08-07	2011-03-15	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8383094B2 (en)	2008-10-01	2013-02-26	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8729077B2 (en)	2008-11-28	2014-05-20	Glaxosmithkline Llc	Anti-viral compounds, compositions, and methods of use
CA2750577A1 (en)	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
WO2010065674A1 (en)	2008-12-03	2010-06-10	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
SG172352A1 (en)	2008-12-23	2011-07-28	Abbott Lab	Anti-viral compounds
EP2393359A4 (en)	2009-02-09	2012-10-03	Enanta Pharm Inc	COMPOUND DIBENZIMIDAZOLE DERIVATIVES
TWI438200B (zh)	2009-02-17	2014-05-21	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
WO2010096462A1 (en)	2009-02-17	2010-08-26	Enanta Pharmaceuticals, Inc	Linked diimidazole derivatives
WO2010094977A1 (en)	2009-02-23	2010-08-26	Arrow Therapeutics Limited	Novel biphenyl compounds useful for the treatment of hepatitis c
US20120040977A1 (en)	2009-02-23	2012-02-16	Presidio Pharmaceuticals, Inc.	Inhibitors of hcv ns5a
RU2544010C2 (ru)	2009-02-27	2015-03-10	Энанта Фармасьютикалс, Инк.	Ингибиторы вируса гепатита с
US8709999B2 (en)	2009-03-27	2014-04-29	Presidio Pharmaceuticals, Inc.	Substituted bicyclic HCV inhibitors
SG174883A1 (en)	2009-03-27	2011-11-28	Presidio Pharmaceuticals Inc	Fused ring inhibitors of hepatitis c
DK2410844T3 (en)	2009-03-27	2016-07-04	Merck Sharp & Dohme	Inhibitors of hepatitis C virus replication
US8796466B2 (en)	2009-03-30	2014-08-05	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
TWI476190B (zh)	2009-03-30	2015-03-11	必治妥美雅史谷比公司	Ｃ型肝炎病毒抑制劑
US8143414B2 (en)	2009-04-13	2012-03-27	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US9278922B2 (en)	2009-04-15	2016-03-08	Abbvie Inc.	Anti-viral compounds
MX2011011136A (es)	2009-04-24	2011-11-18	Tibotec Pharm Ltd	Eteres diarilicos.
EP2430015B1 (en)	2009-05-12	2015-06-17	Merck Sharp & Dohme Corp.	Fused tricyclic compounds useful for the treatment of viral diseases
HUE030465T2 (hu) *	2009-05-13	2017-05-29		Antivirális vegyületek
US8211928B2 (en)	2009-05-29	2012-07-03	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US8138215B2 (en)	2009-05-29	2012-03-20	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2435421A1 (en)	2009-05-29	2012-04-04	Schering Corporation	Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
JP2012528195A (ja)	2009-05-29	2012-11-12	メルク・シャープ・アンド・ドーム・コーポレーション	Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
EA020031B1 (ru) *	2009-06-11	2014-08-29	Эббви Бахамаз Лтд.	Противовирусные соединения
WO2010148006A1 (en)	2009-06-16	2010-12-23	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
WO2011004276A1 (en)	2009-07-06	2011-01-13	Pfizer Limited	Hepatitis c virus inhibitors
AU2010274001A1 (en)	2009-07-16	2012-02-23	Vertex Pharmaceuticals Incorporated	Benzimidazole analogues for the treatment or prevention of Flavivirus infections
WO2011015658A1 (en)	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Bis-benzimidazole derivatives as hepatitis c virus inhibitors
WO2011015657A1 (en)	2009-08-07	2011-02-10	Tibotec Pharmaceuticals	Phenyl ethynyl derivatives as hepatitis c virus inhibitors
AU2010291215A1 (en)	2009-09-03	2012-02-23	Janssen Sciences Ireland Uc	Bis-benzimidazole derivatives
CN102480971B (zh)	2009-09-04	2014-11-26	杨森制药公司	化合物
WO2011031934A1 (en)	2009-09-11	2011-03-17	Enanta Pharmaceuticals, Inc.	Hepatitis c virus inhibitors
US9156818B2 (en)	2009-09-11	2015-10-13	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8415374B2 (en)	2009-10-12	2013-04-09	Bristol-Myers Squibb Company	Combinations of hepatitis C virus inhibitors
WO2011050146A1 (en)	2009-10-23	2011-04-28	Glaxosmithkline Llc	Chemical compounds
UA108211C2 (uk)	2009-11-04	2015-04-10	Янссен Рід Айрленд	Бензімідазолімідазольні похідні
US20110274648A1 (en)	2009-11-11	2011-11-10	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110269956A1 (en)	2009-11-11	2011-11-03	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
US20110281910A1 (en)	2009-11-12	2011-11-17	Bristol-Myers Squibb Company	Hepatitis C Virus Inhibitors
EP2503881B1 (en)	2009-11-25	2015-05-13	Merck Sharp & Dohme Corp.	Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
TWI429645B (en)	2009-12-04	2014-03-11		Proline derivatives
US8653070B2 (en)	2009-12-14	2014-02-18	Enanta Pharmaceuticals, Inc.	Hepatitis C virus inhibitors
US8377980B2 (en)	2009-12-16	2013-02-19	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
MX2012006877A (es)	2009-12-18	2012-08-31	Idenix Pharmaceuticals Inc	Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado.
US20110152246A1 (en)	2009-12-18	2011-06-23	Intermune, Inc.	Novel inhibitors of hepatitis c virus replication
AU2010341537A1 (en)	2009-12-22	2012-08-09	Merck Sharp & Dohme Corp.	Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
MX2012007420A (es)	2009-12-24	2012-07-23	Vertex Pharma	Analogos para el tratamiento o prevencion de infecciones de flavivirus.
WO2011091446A1 (en)	2010-01-22	2011-07-28	Glaxosmithkline Llc	Chemical compounds
PE20130244A1 (es)	2010-01-25	2013-03-10	Enanta Pharm Inc	Inhibidores del virus de la hepatitis c
JP2013518062A (ja)	2010-01-28	2013-05-20	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃ型肝炎阻害化合物

2010
- 2010-03-26 TW TW099109167A patent/TW201038559A/zh unknown
- 2010-04-05 US US12/754,169 patent/US8143301B2/en active Active
- 2010-04-06 JP JP2012504758A patent/JP5558556B2/ja not_active Expired - Fee Related
- 2010-04-06 AU AU2010234608A patent/AU2010234608B2/en not_active Ceased
- 2010-04-06 PE PE2011001706A patent/PE20120533A1/es not_active Application Discontinuation
- 2010-04-06 MX MX2011010478A patent/MX2011010478A/es active IP Right Grant
- 2010-04-06 EA EA201171208A patent/EA018793B1/ru not_active IP Right Cessation
- 2010-04-06 CN CN201080025741.5A patent/CN102803249B/zh not_active Expired - Fee Related
- 2010-04-06 SG SG2011069861A patent/SG174582A1/en unknown
- 2010-04-06 EP EP10714127.7A patent/EP2417126B1/en not_active Not-in-force
- 2010-04-06 CA CA2757963A patent/CA2757963A1/en not_active Abandoned
- 2010-04-06 NZ NZ595186A patent/NZ595186A/xx not_active IP Right Cessation
- 2010-04-06 BR BRPI1010506A patent/BRPI1010506A2/pt not_active IP Right Cessation
- 2010-04-06 ES ES10714127.7T patent/ES2502667T3/es active Active
- 2010-04-06 WO PCT/US2010/030032 patent/WO2010117977A1/en not_active Ceased
- 2010-04-06 MY MYPI2011006293A patent/MY152971A/en unknown
- 2010-04-06 KR KR1020117026556A patent/KR20120133366A/ko not_active Ceased
- 2010-04-09 AR ARP100101218A patent/AR076274A1/es unknown
2011
- 2011-09-11 IL IL215095A patent/IL215095A0/en not_active IP Right Cessation
- 2011-09-28 ZA ZA2011/07095A patent/ZA201107095B/en unknown
- 2011-10-06 CO CO11132299A patent/CO6440581A2/es active IP Right Grant
- 2011-10-07 CL CL2011002524A patent/CL2011002524A1/es unknown

Also Published As

Publication number	Publication date
JP2012523415A (ja)	2012-10-04
EA018793B1 (ru)	2013-10-30
BRPI1010506A2 (pt)	2016-07-26
WO2010117977A1 (en)	2010-10-14
US20100260708A1 (en)	2010-10-14
CO6440581A2 (es)	2012-05-15
JP5558556B2 (ja)	2014-07-23
ES2502667T3 (es)	2014-10-03
IL215095A0 (en)	2011-11-30
MX2011010478A (es)	2011-10-17
AR076274A1 (es)	2011-06-01
ZA201107095B (en)	2013-03-27
PE20120533A1 (es)	2012-05-09
EP2417126A1 (en)	2012-02-15
US8143301B2 (en)	2012-03-27
KR20120133366A (ko)	2012-12-10
AU2010234608A1 (en)	2011-10-06
TW201038559A (en)	2010-11-01
NZ595186A (en)	2013-06-28
EA201171208A1 (ru)	2012-05-30
AU2010234608B2 (en)	2016-04-14
CN102803249A (zh)	2012-11-28
CN102803249B (zh)	2014-09-10
MY152971A (en)	2014-12-15
EP2417126B1 (en)	2014-07-02
CA2757963A1 (en)	2010-10-14
SG174582A1 (en)	2011-10-28

Publication	Publication Date	Title
CL2011002524A1 (es)	2012-03-23	Compuestos derivados de 1,3-diazol-fenil-(etinil, etenil o ciclopropil)-fenil-1,3-diazol sustituidos, inhibidores ns5a; composicion farmaceutica que los comprende y su uso en tratamiento de la hepatitis c.
CL2013002939A1 (es)	2014-07-04	Compuestos derivados de nucleosidos 2´-sustituidos , inhibidores ns5a; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
LTC2340031I2 (lt)	2022-06-27	Gdf gaudyklės, skirtos naudoti anemijos gydymui
CL2008000066A1 (es)	2008-08-01	Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CL2011000527A1 (es)	2011-08-12	Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
BRPI0922233A2 (pt)	2018-05-29	compostos, composições farmacêiticas e métodos para uso no tratamento de síndromes metabólicas.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2008001234A1 (es)	2008-09-22	Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
CL2013001338A1 (es)	2014-03-28	Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2011001333A1 (es)	2011-10-28	Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
BRPI0907663A8 (pt)	2018-08-07	composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
CL2011000846A1 (es)	2011-09-30	Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007000806A1 (es)	2008-05-30	Compuestos derivados de heteropentaciclos sustituidos; proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0913739A2 (pt)	2015-08-18	Composição líquida, método, e, uso de composição
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
DK2120999T3 (da)	2012-12-03	Farmaceutiske sammensætninger omfattende Activin-ActRIIA antagonister samt anvendelse deraf ved forebyggelse eller behandling af multipelt myelom
CL2013003472A1 (es)	2014-08-18	Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras.
CL2012002250A1 (es)	2013-02-08	Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer.
BRPI0819299A2 (pt)	2014-10-07	Uso de composição, e, composição contendo proteína
WO2011160024A3 (en)	2013-07-18	Compounds useful as antiviral agents, compositions, and methods of use
BR112012022879A2 (pt)	2016-06-14	composto, composição farmacêutica, uso do composto e método de tratamento
CL2014002348A1 (es)	2015-01-23	Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
CL2007003672A1 (es)	2008-07-25	Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.